IL-6 as a predictor of survival rate in liver metastatic breast cancer patients with Covid-19 infection: A case series.

Breast cancer is the most common type of cancer in women, with 30 % being metastatic breast cancer. Cancer is known to be a comorbid Covid-19 infection. Interleukin-6 (IL-6) is one of the findings of inflammatory activity due to Covid-19 infection. We report IL-6 levels as a prognostic factor for survival rate in patients with liver metastatic breast cancer. We report five cases of liver metastatic breast cancer with various types of primary breast cancer. All patients are infected with Covid-19. IL-6 levels were reported to be elevated in all five patients. All patients were treated according to the national guidelines for the care of Covid-19 patients. All patients are reported to have deceased after being treated for Covid-19 infection. Metastatic breast cancer has a low prognostic rate. Cancer has been recognized as one of the comorbidities and increases the severity and mortality of Covid-19 infection. Elevated levels of IL-6 are caused by an immune response to infection, and can worsen the outcome of breast cancer patients. Changes in IL-6 levels implicate the survival rate of metastatic breast cancer patients and outcomes during the treatment of Covid-19 infection. Elevated levels of IL-6 can be a prognostic factor of the survival rate of metastatic breast cancer patients during the treatment of Covid-19 infection. • Breast cancer is the most common type of cancer in women, with 30% of them being metastatic breast cancer. • The liver is the third most common target for cancer cell metastasis. • Covid-19 infection can initiate an immune response and worsen the outcome of patients with comorbidities, one of which is cancer. • Interleukin 6 (IL-6) is one type of proinflammatory cytokine that arises as a result of the immune response to Covid-19 infection. • In this case series report, changes in IL-6 levels can be a predictor of survival in patients with liver metastatic breast cancer. [ABSTRACT FROM AUTHOR]

Copyright of International Journal of Surgery Case Reports is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)